Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis

doi:10.3748/wjg.v12.i47.7568

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 47

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5703)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

554

HTML

4749

Figures (1-5)

400

Sum=5703

Dec 21, 2006 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Dec 21, 2006; 12(47): 7568-7577
Published online Dec 21, 2006. doi: 10.3748/wjg.v12.i47.7568

Full Size Figure Download Figure

Figure 4 Release of interle-ukin-1 receptor antagonist (IL-1ra) and IL-10 in the Adacolumn during Adacolumn GMA in patients with active ulcerative colitis. Column outflow returns to the patients. Elevated IL-1ra and IL-10 (both anti-inflammatory) in the column outflow is potentially very significant (see text for comments on IL-1ra and IL-10).

Citation: Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577
URL: https://www.wjgnet.com/1007-9327/full/v12/i47/7568.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i47.7568